



**PRESS RELEASE  
FOR IMMEDIATE RELEASE**

---

**Medicago announces two presentations at the 2008 AAPS National Biotechnology Conference**

**Quebec City, Quebec, June 23, 2008** — Medicago Inc. (TSX-V:MDG) (the “Company”), today announced that it will be presenting an overview of its development of vaccines generated from plant-made Virus-Like Particles and unique technology platform at the 2008 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, from June 22-25, 2008, at the Metro Convention Centre in Toronto, Ontario. Dr. Louis Vezina, Medicago’s Chief Scientific Officer will give a presentation on “*How to Produce Therapeutic Vaccines in Plants*” in a Plenary Session entitled “Pharmaceutical Biotechnology - the Next Steps”, today at 8:30 am EDT. Ms. Irene Clement, Acting Vice President Regulatory Affairs will give a presentation on “*Production and Characterization of Plant-based Vaccines and Therapeutic Antibodies*” in a Session entitled “Plant-based Biologicals: Developmental and Regulatory Aspects” today at 1:00 pm EDT.

**About Medicago**

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at [www.medicago.com](http://www.medicago.com).

***Forward- Looking Statements***

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

**Contact:**

**Medicago, Inc.**  
Andy Sheldon  
President and CEO  
(418) 658-9393

**Investor relations**

**The Equicom Group Inc.**  
Arianna Vanin  
(514) 844-4680  
[avanin@equicomgroup.com](mailto:avanin@equicomgroup.com)